T(H)17 cells ... Sorting the good out from the bad by Li, Junwei et al.
RESEARCH HIGHLIGHT OPEN
TH17 cells…Sorting the good out from the bad
Junwei Li1, Le Jiang1, Yongxiang Yi2 and Pradeep Kumar Sacitharan3,4
Signal Transduction and Targeted Therapy           (2020) 5:207 ; https://doi.org/10.1038/s41392-020-00316-2
A recent article by Wu et al.1 demonstrated how targeting
inflammatory TH17 cells can be achieved by blocking glycolysis
pathway genes. These findings could lead to potential drugs to
selective target “bad” inflammatory TH17 cells, while not disturb-
ing “good” homeostatic TH17 cells in patients with autoimmune
diseases.1
Animal models and human studies have showed a key role for
TH17 cells in the immune system’s defense against bacteria and
fungi, as well as the development of autoimmune diseases,
mediated by the secretion of IL-17.2 In addition, antigen-
presenting cells, such as dendritic cells during the immune
response, secrete IL-23, which in turn activates TH17 cells.
2 The
essential role of homeostatic TH17 cells in the immune response can
be exacerbated into autoimmunity whereby TH17 cells turn
pathogenic and drive tissue damage and pathogenesis in diseases,
such as psoriasis, multiple sclerosis, and rheumatoid arthritis.3,4
Targeting pathogenic TH17 cells can treat autoimmune diseases,
but existing approaches also inhibit homeostatic TH17 cells, thereby
increasing the risk of infection.5 Hence, finding the differences
between these two types of TH17 cells is essential to understand
how to target pathogenic TH17 cells and not to disturb homeostatic
TH17 cells. The authors wanted to decipher the difference between
the cellular metabolism of homeostatic and pathogenic TH17 cells.
The authors at first used an established mouse model of
multiple sclerosis (Fig. 1), called experimental autoimmune
encephalomyelitis (EAE), alongside mouse-knockout mosaic
experiments to selectively differentiate pathogenic compared to
homeostatic cells. Analysis of these elegant experiments revealed
that the pathogenic cells were mostly TH17 cells. Furthermore,
gene expression studies showed that pathogenic TH17 cells had a
higher expression of genes associated with glycolysis compared to
homeostatic TH17 cells. The authors went on to use sophisticated
CRISPR-knockout mice studies and bone marrow chimeric
experiments to tease out which genes in the glycolysis pathway
were important to pathogenic TH17 cells. The team found that the
gene Glucose Phosphate Isomerase 1 (Gpi1) is selectively required
by pathogenic but not homeostatic TH17 cells. Mice containing
cells deficient in Gpi1 were unable to induce EAE.
At this point, the data showed that Gpi1 was dispensable in the
homeostatic model while other glycolysis genes are not. Wu et al.
hypothesized that the pentose phosphate pathway (PPP) might
maintain some glycolytic activity in the Gpi1 KO cells and thus
compensate for Gpi1 deficiency. Data from both in vivo and
in vitro experiments showed a significant increase in PPP activity
in the Gpi1 KO TH17 cells compared to controls, indicating that
Gpi1 deficiency maintains active glycolytic flux through PPP. The
authors went on to knock out both Gpi1 and G6pdx, which
catalyzes the initial oxidative step in the PPP, to further test
whether PPP activity compensates for Gpi1 deficiency in vivo. The
Gpi1/G6pdx double KO reduced cell number by about 75%,
demonstrating that in vivo PPP activity maintains viability of
homeostatic TH17 cells lacking Gpi1.
Next, the authors wanted to elucidate the impact of Gpi1
deficiency on aerobic glycolysis activity. A reduced lactate
production alongside a higher ATP-linked respiration rate was
observed in Gpi1 KO cells. These two results alongside additional
in vivo validation pointed to the fact that mitochondrial respiration
through pyruvate oxidation compensates for Gpi1 deficiency in
homeostatic TH17 cell differentiation. At this stage, the authors
knew that the PPP and mitochondrial respiration were compensat-
ing for Gpi1 deletion, but this suggested a partial metabolic
redundancy for Gpi1 via another compensatory mechanism. The
authors performed kinetic testing alongside glucose labeling
experiments, and showed that the loss of Gpi1 led to a reduction
of glucose uptake and abundance of pyruvate and lactate.
Altogether, these data suggested that the reduced amount of
glucose metabolized in Gpi1 KO cells via PPP could support the
production of glycolytic intermediates and maintain pyruvate
oxidation. In addition, Gpi1 KO cells increased their mitochondrial
respiration to compensate for the loss of glycolytic flux.
For the final important question in this paper, the authors
wanted to understand why pathogenic TH17 cells are particularly
sensitive to Gpi1 deficiency. They hypothesized that inflamed
tissue that is hypoxic may lead to impaired mitochondrial
respiration, resulting in an inability to generate ATP to compen-
sate for energy loss due to Gpi1 deficiency in these tissues. The
authors cultured TH17 cells in hypoxic and normoxic conditions to
show that Gpi1 KO cells had decreased lactate production in both
normoxic and hypoxic conditions. However, Gpi1 KO cells only
demonstrated reduced intracellular ATP in hypoxic conditions.
Furthermore, in vivo analysis of inflamed tissue in an EAE model
displayed decreased oxygen availability that was regulated by the
oxygen sensor Hif1a in pathogenic TH17 cells.
Overall, Wu et al. revealed that TH17 cells increase glycolysis
activity to adapt to the hypoxic environment in EAE. In this setting,
reduced mitochondrial respiration cannot compensate for the loss
of glycolytic ATP production upon Gpi1 inactivation, leading to
energy crisis and cell elimination. These results also provide the
first proof that Gpi1 inhibition may be a therapeutic option in
disease states that display hypoxic microenvironments. However, we
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cannot exclude the possibility that other environmental factors, not
only oxygen levels, may also play a role in these disease settings.
Clinical trials and possible ex vivo experiments using disease tissue
or cultured cells are required to validate these results further.
Nonetheless, this paper opens a larger possibility of specifically
inhibiting pathogenic cells by metabolic targeting of selective
redundant cellular components, which opens up a myriad of
therapeutic opportunities in different disease microenvironments.
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Fig. 1 The glycolysis gene Gpi1 is required for homeostatic TH17 cells in normal tissue whereby high oxygen levels allow pentose phosphate
pathway (PPP) and OXPHOS to compensate for the loss of Gpi1. In hypoxic inflamed tissue, the loss of OXPHOS occurs, thus making Gpi1
essential for the survival of pathogenic TH17 cells. Hence, metabolic redundancy varies according to the microenvironment, and Gpi1 may be a
therapeutic target in certain settings
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